


+ REDUCING OPIOID-RELATED HARM

*A hospital pharmacy landscape paper
for the Medicines Leadership Forum*

—
July 2018



Contents

About SHPA.....	4
Acknowledgements.....	4
Introduction from SHPA President Professor Michael Dooley	5
Executive summary	6
Methodology	7
Key Findings	8
Section 1: Service provision.....	8
Section 2: Patient journey	12
Section 3. Use of medicines	15
Section 4. Transition of care	18
Section 5: Reporting by hospital pharmacies	20
Section 6. Education and quality improvement activities.....	21
Section 7. Innovation	22
Section 8. Variation in responses between metropolitan and regional hospitals	22
Discussion of findings and implications for service provision.....	25
1. Service provision.....	25
2. Patient journey	26
3. Use of medicines to treat acute pain in opioid naive patients.....	28
4. Hospital pharmacy and the transition of care	30
5. Reporting on opioid use	30
6. Education	31
7. Innovation in practice	31
8. Next steps	31
Conclusion	32

Table of Figures

Figure 1.	Does your hospital site provide Acute Pain Service for inpatients? (Answer = Yes).....	8
Figure 2.	Does your hospital site provide a formal opioid/analgesia stewardship program for inpatients?	9
Figure 3.	What are the barriers to your hospital site introducing the services that are currently NOT offered?	10
Figure 4.	Public vs Private Hospitals: What are the barriers to your hospital site introducing the services that are currently NOT offered?	11
Figure 5.	Do pharmacists routinely discuss, review and document patients' prior opioid use upon admission during the medication reconciliation process?.....	12
Figure 6.	Do ward/medical unit pharmacists routinely give advice to patients about appropriate pain management and analgesia use?	14
Figure 7.	What factors are used to prioritise clinical pharmacy services for patients on these wards?	14
Figure 8.	When treating acute pain in opioid naive patients, what treatments does your hospital site commonly prescribe, administer or utilise?.....	15
Figure 9.	South Australia vs Australia: When treating acute pain in opioid naive patients, what treatments does your hospital site commonly prescribe, administer or utilise?.....	16
Figure 10.	Do ward/medical unit pharmacists review the last 48 hours of analgesia use to determine appropriate prescription of analgesia medicines and quantity upon discharge?	16
Figure 11.	If opioid analgesia were not administered in the 48 hours prior to discharge, are opioid analgesia supplied on discharge just in case patients might require them?.....	17
Figure 12.	To improve patient flow and bed availability, does your hospital site undertake any of the following?	17
Figure 13.	Do patients receive advice from non-pharmacists on analgesia medicines at the point of discharge, excluding day cases?	18
Figure 14.	Does the ward/medical unit pharmacist provide any of these documents to the patient's community care providers (i.e. GP, community pharmacy, care facility, carer)?.....	19
Figure 15.	How often and to whom does the pharmacy department provide information/feedback regarding opioid prescribing and supply?	20
Figure 16.	How is information contained in opioid prescribing and supply reports utilised by your hospital?	21
Figure 17.	Metropolitan vs Regional/rural: Do ward/medical unit pharmacists review the last 48 hours of analgesia use to determine appropriate prescription of analgesia medicines and quantity upon discharge?	23
Figure 18.	Metropolitan vs Regional/rural: Does the ward/medical unit pharmacist provide any of these documents to the patient's community care providers? (Type of document)	23
Figure 19.	Metropolitan vs Regional/rural: Does the ward/medical unit pharmacist provide any of these documents to the patient's community care providers? (Frequency) (Regularly defined as at least annually)	24

About SHPA

The **Society of Hospital Pharmacists of Australia** (SHPA) is the national, professional, for-purpose organisation for leading pharmacists, technicians and pharmacy assistants working across Australia's health system. Established in 1941, SHPA provides a range of education, advocacy and policy services including a structured two-year residency program for post-internship pharmacists and 24 specialty practice streams for members. SHPA is also a founding member of Pharmacy Development Australia which supports the Advanced Practice Collaborative, the only program in Australia recognising advancing and advanced pharmacy practitioners.

Embedded in multidisciplinary medical teams and equipped with exceptional medicines management expertise, SHPA members are progressive advocates for clinical excellence, committed to evidence-based practice and passionate about patient care.

Acknowledgements

SHPA would like to thank its Opioid Advocacy Working Group for their dedication to the project: Jane Booth, Thuy Bui, Annabel Calder, Christine Coorey, Paul Firman, Kerry Fitzsimons, Marisa Hodgkinson, Jacinta Johnson, Margaret Jordan, Miriam Lawrence, Daniel Lim, Duncan McKenzie, Peter Samios, Benita Suckling, Penelope Tuffin and Jason Waddell, supported by Johanna de Wever, Jerry Yik, Courtney Munro and Maria Khokhar from the SHPA secretariat.

Introduction from SHPA President Professor Michael Dooley

The harm caused by opioids is well-known in Australia and internationally. The experience internationally has been that the rise in harm has been driven by a range of factors including; unrealistic expectations of pain management, over prescribing and lack of evidence-based educational programs for health professionals. SHPA is one of many organisations currently considering possible interventions, alongside parliamentary reports from Victorian and New South Wales governments as well as consultation from the Therapeutic Goods Administration undertaken in the first quarter of 2018. These significant investigations into prescription drug misuse have been primarily focused on the use of opioids in the community, reflecting the well-known reality that the majority of opioid prescribing and dispensing is completed by General Practitioners and Community Pharmacists respectively.

However, the patient journey towards opioid harm begins earlier than this, with recent research identifying that for a significant number of patients, the provision of opioids post-surgery is a key factor that can lead to harm. This 'iatrogenic dependence' has been recently recognised as a key driver for future dependence.

As demand for surgery in public and private hospitals continues to grow, the importance of pain management, and the prescribing and supply of medicines for surgical patients when discharged from hospital also increases. In 2016-2017 there were over a million surgeries in public hospitals and 1.5 million surgeries in private hospitals. Over 2.2 million separations involved elective surgery, 33% in public hospitals and 67% in private hospitals, following which the prescribing, administration and dispensing of opioids is commonplace.

Given that hospital-initiated opioid use is frequent and can induce significant potential harm, SHPA has a unique opportunity to provide member expertise and insights as strategies that inform high-quality care and minimise risk associated with these medications. Considering the lack of evidence regarding current hospital practices associated with opioid prescribing, administration and dispensing in hospitals, the work presented here is conceived as a landscape snapshot of practice focusing on the provision of clinical pharmacy services to patients who are likely to be prescribed opioids after surgery. It has now evolved into a broader initiative with our members, medical colleagues and government stakeholders as we aim to collectively consider our role in the prevention and mitigation of opioid harm.

The pharmacy workforce represented by SHPA has been at the forefront of the development and expansion of clinical pharmacy services for decades. In addition to undergraduate education and supervised training, our members have embraced structured residencies, postgraduate studies and Advanced Practice credentialing. They are committed to the Australian Charter of Healthcare Rights guiding principles and to providing healthcare that is safe, effective, patient-centred, timely, efficient and equitable. Now we seek to collaborate with other healthcare practitioners and organisations to prevent unnecessary harm caused by opioids initiated in the hospital setting by beginning an important conversation about services in hospitals, innovation and collaborations.



Professor Michael Dooley

President

The Society of Hospital Pharmacists of Australia

Executive summary

Opioid-related harm

The harm caused by opioids is well-known in Australia and internationally; the misuse of pharmaceuticals is now the greatest cause of drug-related death in Australia¹. The experience internationally has been that the rise in harm has been driven by a range of factors including unrealistic expectations of pain management, over-prescribing, and lack of evidence-based educational programs for health professionals^{2,3}.

The medical use of opioids prescribed in a hospital setting has been identified as a key risk for ongoing use⁴. As opioid use often begins with the treatment of acute pain⁵ and given that more than 2.2 million surgeries were undertaken in Australia in 2016-2017⁶, this has substantial implications for the treatment of acute pain post-surgery.

Landscape snapshot of practice in Australian hospitals

As the peak body for hospital pharmacists, SHPA was keen to understand the role and activities of hospital pharmacists in the care of patients receiving opioids in hospital after undergoing surgery. SHPA is aware that a number of regulatory responses to reduce harms are also being considered.

This paper comprises the results of an online survey of hospital pharmacists working in public and private hospitals. The results were informed by 135 Australian hospital facilities and reflect feedback from Directors of Pharmacy, and their delegates, regarding pharmacy service provision, workload, prescribing practice and dispensing activities. Whilst providing useful insights, the results cannot be considered to represent all hospitals or hospital pharmacies in Australia.

Key findings

- The provision of specialised services for patients with pain is varied, with a considerable range reported in relation to the provision of acute pain services and pain management clinics for post-surgical patients, especially in regional and rural areas.
- Sizeable gaps exist in the provision of medication reconciliation, clinical review, analgesia and pain management advice and review of analgesia use before discharge, for patients attending both public and private hospitals.
- Pharmacists report extremely high use of sustained-release opioids in treatment of acute pain for opioid naive surgical patients.
- Current practices relating to the prescribing and dispensing of opioids at discharge result in excess quantities given to patients with the potential to lead to preventable harm.
- Information provided at hospital discharge (medication lists, discharge summaries and medication plans) is inconsistent and many patients and their General Practitioners are not receiving the appropriate information.
- Clinical pharmacy capacity at hospitals with substantial surgical patient loads may not meet patient need.
- Risk factors for opioid harm are not commonly prioritised by contemporary clinical pharmacy services.
- Clinical pharmacy prioritization tools used in a hospital setting require review to ensure they address the risk of long-term misuse and associated harms.
- A range of innovative strategies which enable improved patient care alongside prescriber and governance support (including opioid stewardship) should be considered for expansion. These results also provided evidence of the value of hospital pharmacies equipped to innovate and empowered to address public health challenges.
- Statewide interventions which capitalize on pharmacy expertise through effective governance and engagement across pharmacy, medical and nursing workforces delivered positive outcomes in areas of prescribing, supply and prescriber education.

Next steps

This work was intended to provide an insight into current practices and to identify areas for innovation. SHPA's inaugural Medicines Leadership Forum in July 2018 will provide an opportunity for discussion of the key findings with a range of medical and health stakeholders and result in the development of recommendations. These will be published by SHPA in a report to support further discussions with stakeholders including hospitals regarding service provision, clinical care and governance.

Methodology

In May 2018, SHPA conducted a cross-sectional landscape survey on the use of opioids post-surgery to inform our work in this area. The survey questions and methodology were reviewed by the Advocacy Opioid Working Group consisting of SHPA Branch representatives, subject matter experts and the SHPA advocacy team.

The survey was targeted at Directors of Pharmacy and their delegates. Directors of Pharmacy are typically responsible for the management of pharmacy policy, procedure and hospital practice, and have a firm understanding of dispensing and discharge practices, and service provision levels in their health service. They were encouraged to answer the survey on behalf of their service or to delegate to a staff member with awareness of the relevant services provided. All information provided represents the informed opinion of the respondent.

The survey was conducted using the online survey tool; 'SurveyMonkey' and was open for two weeks. Emails including the survey link were sent to 250 Directors of Pharmacy on Wednesday 9 May 2018, with a reminder prior to the survey closing. All participation was voluntary.

Survey respondents were advised to fill in a separate survey entry for each hospital site within the one hospital network undertaking surgery, given that it is widely accepted practices and service provision between individual sites within the same network can vary significantly. Information identifying each site was treated confidentially.

A total of 170 responses were received. Respondents who completed less than 55% of the survey were excluded from the study. Out of the 170 responses, 135 met the inclusion criteria. To control for bias, survey responses were anonymous so that hospitals could not be identified. The responses were grouped into identified themes. The responses were analysed by an independent researcher to avoid reporting bias.

Demographics

Of the 135 respondents, there was proportionate national representation with a slightly higher representation from Victorian hospitals – reflective of the SHPA membership. 40% of the responses were from Victoria, 19% New South Wales, 15% Queensland, 11% Western Australia, 8% South Australia, 3% Australian Capital Territory, 2% Tasmania and 2% from Northern Territory. Geographically, there was good representation from hospital sites in metropolitan and non-metropolitan areas with 59% of hospitals from metropolitan regions, and the remaining 30% in regional and 11% in rural areas.

Majority of the survey responses came from public acute group A/public acute group B hospitals with 39%. Principal referral hospitals equated to 24% of the responses, 16% public acute group C/public acute group D, 11% private acute group A/private acute group B and 3% private acute group C/private acute group D. The remaining hospital sites were either children's/women's/combined women's and children's, same day hospitals, sub-acute and non-acute hospitals (public or private rehabilitation) or other.

Key Findings

Section 1: Service provision

1.1 Provision of acute pain services

Acute pain service

A team within a hospital dedicated to the management of patients experiencing acute pain. Has responsibility for day-to-day management of patients with acute pain and for providing an appropriate level of care and monitoring⁷.

Pharmacists in acute pain services

The role of the pharmacist in an acute pain service is to promote appropriate use of analgesia medicines, evaluate new analgesia for formulary addition, and conduct medication-use evaluations, outcomes research and pharmacoeconomic analyses⁸.

The majority of respondents (61%) indicated that their hospital had an established acute pain service for inpatients, **20% indicated their hospital had no acute pain service**, with the balance (19%) having a limited service. The gap in acute pain services was more concentrated in smaller and private hospitals. Public hospitals were more likely to have an acute pain service than private hospitals (69% vs 42%) while hospitals categorised as public and or private acute A and B hospitals, were more likely to have an acute pain service than public and private acute C and D hospitals (67% vs 19%).




Figure 1. Does your hospital site provide Acute Pain Service for inpatients? (Answer = Yes)

Most respondents (72%) considered that **acute pain services were not commensurate with demand and should be expanded to meet the needs of patients**. Results were broadly consistent across hospital types, and between metropolitan, regional and rural hospitals. Principal referral hospitals were the best serviced with 44% of respondents believing service levels were commensurate to demand and patient need.

1.2 Provision of opioid stewardship programs

Opioid stewardship

Opioid stewardship (also called analgesia stewardship) is a hospital-wide strategy adopted from antimicrobial stewardship, that provides care for patients using opioids to treat pain. The strategy ensures safe, rational prescribing of opioids to optimise pain management in the care of patients. Opioid stewardship provides an opportunity for pharmacists to take a leadership role in pain management⁹.

Opioid Stewardship Pharmacist

The focus of an opioid stewardship pharmacist is to actively optimise appropriate use of analgesia, decrease serious adverse effects and improve patient care. The role may provide clinical care in related services such as acute pain services, or pain clinics depending upon service capacity¹⁰.

Less than five per cent of respondents indicated that their hospitals had a formal opioid/analgesia stewardship program; whilst 13% had a limited/informal program, although no further information was available to detail what these programs entailed. Combined, this indicates less than a fifth of hospitals have some form of – even if limited – hospital-wide stewardship model in place to reduce potential opioid harm.




Figure 2. Does your hospital site provide a formal opioid/analgesia stewardship program for inpatients?

Hospitals providing either a formal or informal opioid/analgesia stewardship service were more concentrated in the principal referral and A/B hospital categories, regardless of private or public status. Of the 24 respondents indicating their hospital had at least a limited opioid stewardship program, 96% indicated the hospital also had a limited acute pain service, and 58% also had a limited ambulatory pain management clinic for post-surgical patients. Respondents across all hospital types and settings were overwhelmingly (nearly 95%) supportive of opioid/analgesia stewardship programs being expanded and reported that their existing services were insufficient to meet patient demand.

1.3 Pain management clinics

Pharmacists in ambulatory pain management clinics

The role of pharmacists in managing patients in an ambulatory pain setting includes providing medicines reconciliation, medication review, therapeutic drug monitoring, interdisciplinary rounds with the medical team to provide optimal inpatient postoperative pain management, clinical assessment of outpatient prescriptions with opioid discharge counselling, and medication evaluation of prescribed pain regimen treatment plan at the post-discharge follow-up appointment¹¹.

Provision of formal pain management clinics for post-surgical patients is uncommon in hospitals (15%) with an additional 13% reported to having a limited or informal program, equating to 27% of respondents. Programs were concentrated in principal referral hospitals, with 50% of principal referral hospitals indicating they have a formal or limited/informal service. Acute A and B hospitals were more likely to have clinics (22% vs 16%) than Acute C and D hospitals, with public hospitals also having slightly higher service provision compared to private hospitals. While the question focused on clinics provided for patients with post-surgical pain, some comments indicated that respondents included clinics providing services for chronic pain as well. A large majority of respondents (87%) considered their service in this area not commensurate with demand or meeting the needs of patients and that it needed to be expanded.

1.4 Barriers to expansion of desired services

Given the majority of respondents felt that existing services were not meeting demand, (acute pain service 72%, opioid/analgesia stewardship 94% and pain management clinic 87%), expansion of acute pain services, opioid stewardship programs and pain management clinics in respondents' hospital sites was well supported. Respondents cited multiple barriers to expansion including a lack of funding, lack of appropriate staff expertise and organisational support.




Figure 3. What are the barriers to your hospital site introducing the services that are currently NOT offered?

Funding from state and/or territory governments (presumably a lack thereof) was the most commonly reported barrier by all respondents. In addition, a lack of organisational support from hospital management, as well as support from medical colleagues and the pharmacy department itself were identified by a large number of respondents. Workforce deficits relating to medical and pharmacy expertise were also acknowledged.

Lack of organisational support from hospital management was reported more frequently for larger hospitals, both public and private. For public hospitals, state/territory funding was the biggest perceived barrier (88%), however 39% of these respondents also cited lack of federal funding; and lack of organisational support from

internal stakeholders (hospital management 59%; medical department 37%; pharmacy department 42%). In contrast, the key barrier reported by private hospitals was lack of support from hospital management (63%).




Figure 4. Public vs Private Hospitals: What are the barriers to your hospital site introducing the services that are currently NOT offered?

1.5 Pharmacy involvement in hospital pain services

Pharmacist

A healthcare professional with tertiary qualifications and registered with the Australian Health Practitioners Regulation Agency, who use their expertise in medicines to optimise health outcomes and minimise medication misadventure. Pharmacists apply their knowledge of medicines to promote their safe and effective use. They also provide clinical care to avoid, detect, monitor and manage medication adverse events and medication-related problems that patients may experience¹².

Pain Pharmacist

An emerging role, this encompasses a multidisciplinary approach to support patients with either acute or chronic pain through pharmacy care including recording and resolving medication-related problems, preventing adverse drug reactions, therapeutic drug monitoring and addressing polypharmacy. In addition, the role supports broader service provision by being a central contact point for pain-related queries, attending ward rounds, providing education and conducting audits and research¹³.

A large proportion of survey respondents providing hospital-wide pain management services reportedly did not have pharmacy involvement in that service. Fifty-one percent respondents reported that their acute pain services did not have pharmacist involvement, this was also observed at a rate of 33% for respondents with opioid/analgia stewardship services 86% of respondents with pain management clinics. Reports of clinical pharmacy activity in these services (advising on patient care, being able to refer, being embedded in a multidisciplinary team) was consistently under 10%. In most cases, involvement of pharmacy relied upon a proactive ward-based pharmacist liaising with the pain service in addition to their standard responsibilities. Reports of rates of clinical pharmacy involvement in opioid/analgia stewardship was limited by low prevalence at present and its informal implementation. Pharmacist involvement in pain management clinics was also extremely uncommon.

Section 2: Patient journey

2.1 Pharmacy services pre-admission

Medicines reconciliation

Process of obtaining, verifying and documenting an accurate list of a patient’s current medications prior to admission to hospital and comparing this list to the admission, transfer, and/or discharge medication orders to identify and resolve discrepancies. At the end of the episode of care the verified information is transferred to the next care provider¹⁴.

Ward Pharmacist

A hospital pharmacist embedded in a hospital ward where they may provide care for patients with varying illnesses who are in that ward. Their duties include participating in medical and multidisciplinary rounds, having direct contact with patients and caregivers, and having access to the complete medical record of a patient, including biologic data and results of diagnostic tests to provide clinical pharmacy services¹⁵.

Terminology used to identify a pharmacist allocated to a patient ward not based in the hospital dispensary.

Medical Unit Pharmacist

A hospital pharmacist embedded in a medical team, whose duties include making rounds with the medical team as well as monitoring drug dispensing, storage, and administration for an area of specialty practice¹⁶.

Terminology used to identify a pharmacist allocated to a medical team not based in the hospital dispensary.

Twenty-three percent of respondents reported to have dedicated clinical pharmacists or a clinical pharmacist working collaboratively in pre-admission clinics to review patients’ prior opioid use, although in some cases this was for high-risk patients only. Pharmacists most often did not attend pre-admission clinics (60%) and therefore the discussion of patients’ prior opioid use was undertaken by other health professionals if performed.

2.2 Pharmacy service at admission

Forty-five percent of respondents reported that prior opioid use was discussed and reviewed with all patients during medication reconciliation process undertaken by the pharmacist. A further 37% indicated that ‘some’ patients were provided this service, but not all. Nine percent of medicine reconciliations were undertaken by non-pharmacists, with 4% of respondents indicating there was no medicines reconciliation at the time of admission. Several responses indicated that the medicines reconciliation undertaken focused only on current medicines and may not identify past opioid use.




Figure 5. Do pharmacists routinely discuss, review and document patients' prior opioid use upon admission during the medication reconciliation process?

2.3 Access to pharmacist advice regarding pain management and analgesia use

Most respondents (93%) indicated there was capacity for pharmacists to provide advice to patients regarding appropriate pain management and analgesia use. This reflects the activities of both those in dedicated roles and with more general responsibilities. However, **such advice was often restricted to patients identified as high-risk (53%)**.

In contrast, **93% of respondents were either never able to, or unable to routinely attend ward rounds** to advise on analgesia including opioid use, with only 7% of respondents doing so routinely. In this cohort, 31% of respondents were only able to attend ward rounds 'if they had time'. The 58% of respondents who did not attend ward rounds include both public hospital respondents (49%) who were unable to participate and private hospital respondents (11%).

In most cases hospitals prioritise the provision of clinical pharmacy services for surgical patients as 78% of responses stated that their surgical wards were staffed by a dedicated pharmacist. In some instances, these were rotating responsibilities shared among the broader pharmacy team day-by-day, rather than a set or fixed position. Sixteen per cent of respondents stated that neither their surgical or perioperative wards had a dedicated pharmacist. Comments indicated that in these circumstances any clinical pharmacy services were provided on an ad-hoc basis by the dispensary.

2.4 Access to clinical pharmacy services

Clinical pharmacy services

Clinical pharmacy services comprise a range of activities, include: medication reconciliation, assessment of current medication management, clinical review, therapeutic drug monitoring and adverse drug reaction management, contributing to the medication management plan, providing medicines information, facilitating the continuity of medication management on discharge or transfer and participating in interdisciplinary ward rounds and meetings¹⁴.

Clinical review

Review of patient-specific clinical information and patient parameters to evaluate their response to medication therapies and to detect and manage potential or actual medicines-related problems¹⁴.

High-risk medicines

A medicine that is deemed high-risk and can cause serious adverse effects and require additional monitoring and clinical pharmacy care, such as:

- insulins and/or oral hypoglycaemic agents
- opioid analgesia
- immune suppressant therapy
- anticonvulsants
- aminoglycosides or vancomycin
- anticoagulants and antithrombotics
- intravenous potassium
- chemotherapy¹⁴.

For pharmacists working in a medical unit or on a ward, providing cognitive clinical pharmacy services to patients is the priority, however comments indicated that meeting demand is a constant challenge. **The majority of pharmacists were expected to prioritise high-risk patients for clinical pharmacy services (53%) rather than having capacity to providing clinical services for all patients (32%)**.




Figure 6. Do ward/medical unit pharmacists routinely give advice to patients about appropriate pain management and analgesia use?

In cases where patients were prioritised, multiple factors were used with existence of multiple chronic conditions/comorbidities (65%), age (59%), concurrent anticoagulant use (55%), renal or hepatic impairment (47%) most common. Additional comments provided by respondents showed **that the process of prioritisation varies considerably between health services** with some organisations using a high-needs patient screening tool or on referral from nursing staff.

Twenty-four percent of respondents indicated that a patient already on opioids prior to admission would be prioritised for clinical pharmacy services, with 17% of respondents prioritising patients with known opioid tolerance and **only 9% for opioid naive patients.**




Figure 7. What factors are used to prioritise clinical pharmacy services for patients on these wards?

Section 3. Use of medicines

3.1. Commonly prescribed analgesia for opioid naive patients – at admission and discharge

Sustained-release oral opioids

Sustained-release (SR) opioids are also referred to as slow, controlled and modified release, and typically dosed twice-daily to provide analgesia for 24 hours. As such, they are intended to be used in the setting of chronic pain, and for patients who require repeated dosing with immediate-release opioid analgesia¹⁷. Presently in Australia there are several opioids available as SR products including hydromorphone, morphine, oxycodone and tapentadol. Each of these medicines is also available as an immediate or conventional release formulation.

Immediate-release opioids

Immediate-release opioids are medicines formulated to release the full dose of the opioid medicine immediately after oral administration. Immediate-release opioids result in relatively rapid drug absorption and onset of analgesic effect, and thus are typically used to treat severe acute pain and breakthrough pain¹⁸.




Figure 8. When treating acute pain in opioid naive patients, what treatments does your hospital site commonly prescribe, administer or utilise?

When treating acute pain in opioid naive patients, respondents reported that hospitals commonly prescribed (in order of prevalence): immediate-release opioids (97%), non-opioid analgesia (96%) sustained-release opioids (oral formulations) (77%), and partial/mixed opioids (74%).

Similarly, at discharge, for acute pain in opioid naive patients commonly prescribed (in order of prevalence) were: immediate-release opioids (97%), non-opioid analgesia (97%), sustained-released opioids (oral formulations) (71%) and partial/mixed opioids (66%). Whilst prescription of sustained-release opioid patches was lower than other medicines, the prescription of opioid patches was still significant with 11% of respondents reporting provision at discharge.

It is of note that South Australia consistently reported lower use of sustained-release opioids compared to the national average.




Figure 9. South Australia vs Australia: When treating acute pain in opioid naive patients, what treatments does your hospital site commonly prescribe, administer or utilise?

3.2 Review of medicine use by post-surgery patients

Pharmacist review of analgesia use prior to discharge was not consistently provided across respondents in either public or private hospitals. **Less than a quarter (23%) of respondents always reviewed the last 48 hours of analgesia use to inform appropriate prescribing upon discharge.** Slightly more (31%) completed a review ‘often’, whilst 28% sometimes completed. A minority (13%) of respondents indicated that a pharmacist ‘rarely’ or ‘never’ reviewed the last 48 hours of analgesia use prior to discharge to determine appropriate prescriptions on discharge, with a few additional comments that reviews took place but did not influence prescribing. In some facilities providing day surgery services it was noted that patients are not present in the hospital long enough to enable this review.




Figure 10. Do ward/medical unit pharmacists review the last 48 hours of analgesia use to determine appropriate prescription of analgesia medicines and quantity upon discharge?

3.3 Supply of opioids at discharge for patients post-surgery

Respondents stated that even when patients’ pain had not required opioid analgesia in the 48 hours prior to discharge, **more than 70% still supplied opioids more often than not to take home ‘just in case’.** Several comments indicate that the amount supplied depended on factors including the patient, the prescriber and on occasion the confidence of the pharmacist.




Figure 11. If opioid analgesia were not administered in the 48 hours prior to discharge, are opioid analgesia supplied on discharge just in case patients might require them?

3.4 Hospital pharmacy services at discharge

In an effort to improve patient flow and bed availability, some respondents indicated that efforts were made to increase the efficiency of discharge by writing up discharge prescriptions before discharge is confirmed (62%) and prior to surgery (21%) as well as dispensing medicines before discharge is confirmed (38%) and before surgery (10%). **Eighteen per cent of respondents indicated their site provided pre-packed analgesia medicines to patients at discharge.** Some respondents provide additional information that these activities were often reconciled before finalisation, undertaken only when exceptional circumstances arose, or in specific clinical settings such as emergency departments.




Figure 12. To improve patient flow and bed availability, does your hospital site undertake any of the following?

3.5 Patient counselling and information about medicine use

Patient medication counselling by a Pharmacist

Involves providing medicines information to patients to improve patient capacity for involvement, engage them in their healthcare and encourage the safe and appropriate use of medicines, enhancing therapeutic outcomes¹⁴.

Thirty-nine percent of respondents ‘always’ provided counselling to patients on their medicine during discharge by a pharmacist, with a further 41% of respondents undertaking this ‘often’. Hospital sites also indicated that elements of discharge counselling are undertaken by other multidisciplinary team members including ward-based nurses (79%) or the discharging doctor (72%).




Figure 13. Do patients receive advice from non-pharmacists on analgesia medicines at the point of discharge, excluding day cases?

Day surgery patients are significantly less likely to receive counselling from a hospital pharmacist on how to use their medicines safely with only 14% of respondents always providing counselling. Additional comments indicated that in many hospitals day surgery patients are not supported by hospital pharmacies at all, which is reflected in the most common response which was ‘No’ (23%). These patients were typically referred to community pharmacies, sometimes attached to the hospital, for medicines to be dispensed.

Section 4. Transition of care

Transition of care

Hospital-based transitional care interventions aim to smooth the transition from the inpatient to the outpatient setting and prevent unnecessary readmissions and adverse events¹⁹.

4.1 Information provided to patient’s GP/ community care provider post discharge

Opioid de-escalation plans

Opioid de-escalation plans are individualised treatment plans with the aim of weaning off opioids when using these medicines to treat acute pain. Opioid de-escalation plans reduced opioid dosing in a scheduled manner to maintain adequate analgesia relief and complementing pain treatment with non-pharmacologic therapies and non-opioid medications²⁰. Also known as tapering or weaning plans.

Medicines list

A medicines list records:

- all the medicines a patient uses, including prescription, non-prescription, over-the-counter, minerals, herbal and natural medicines
- the condition that each medicine is treating
- the dosage quantity and frequency of each medicine to use
- how to use each medicine¹⁴.

Discharge summary

A discharge summary is a collection of information about events during care of a patient by a provider or organisation. The document is produced during a patient's stay in hospital as either an admitted or non-admitted patient and issued when or after the patient leaves the care of the hospital²¹. Discharge summaries typically include the updated medicines list, as well as medicines that have been ceased or require ongoing review in the community.

Pain management plan

This is a document agreed by the patient, the General Practitioner, and pain management team. A pain management plan should specify the goals of therapy, and a timeframe for reaching each goal. The pain management plan can help General Practitioners, emergency department doctors and locum practitioners to provide consistent care²².

Almost all respondents indicated that information was provided to the community care provider, most commonly an updated medicines list (74%), with discharge summaries (46%) being the next most common item. However additional comments from many respondents flagged documents such as an updated medicines list often being provided only for patients identified as high-risk by the pharmacist. **Provision of pain management plans or opioid de-escalation plans were rare with less than 10% of respondents providing either.**




Figure 14. Does the ward/medical unit pharmacist provide any of these documents to the patient's community care providers (i.e. GP, community pharmacy, care facility, carer)?

Section 5: Reporting by hospital pharmacies

Respondents were asked to identify whether the in-hospital pharmacy department currently provided information collected through dispensing or patient review to key hospital audiences and if so, how often. These audiences included Drug and Therapeutic Committees, medical, nursing and within pharmacy departments (i.e. pharmacy management to pharmacy staff), hospital management and local hospital districts.




Figure 15. How often and to whom does the pharmacy department provide information/feedback regarding opioid prescribing and supply?

Overall results showed low levels of regular reporting from pharmacy to all groups. The most common response was that feedback was provided ‘when requested/irregularly’, with reports to medical colleagues, Drug and Therapeutics Committee and intra-pharmacy department being the most common. The second highest response overall was ‘never’. **Results for any regular reporting to any group were negligible.** Six percent of pharmacy departments were tracking opioid prescribing monthly and only a total of 11% of hospitals were doing this regularly (defined as at least on an annual basis).

These reports typically covered information such as hospital-wide medicines use evaluations, medication error and adverse event reports, prescribing and utilisation trends and dispensing reports. Of the respondents who did collate information regarding opioid use, medication error and adverse event reporting was most common at 53%, whilst only approximately one fifth of respondents who did provide reports, included information pertaining to prescribing and utilisation trends, and dispensing reports. Results from medicines use evaluations were reported at a rate of 28%.

When respondents were asked how the information above was utilised, the most common response was discussion of the results among the pharmacy department’s medication safety and quality use of medicines team. Only 28% of respondents stated that this information was used to inform educational activities aimed at doctors, and even less for nurse education (21%).




Figure 16. How is information contained in opioid prescribing and supply reports utilised by your hospital?

Eleven percent of hospitals provide feedback to select medical units with higher use of opioids at least annually. Just below half of hospitals provide information to any audience when requested with a similar portion of respondents ‘never’ been asked for information regarding opioid prescribing or supply. Comments from some respondents indicate that interest exists with informal discussion of opioids occurring in ward rounds and departmental meetings, especially when a formal or informal opioid stewardship service exists. Prescriber-specific utilisation trends (a key element of academic detailing) was extremely uncommon with only 3% reporting on this.

Section 6. Education and quality improvement activities

Prescriber education/prescriber feedback

When prescribers are provided with data on their prescribing habits compared with hospital guidelines, or with other prescribers in the same field of practice²³.

As medicine experts pharmacists play a key role in educating other members of the multi-disciplinary team regarding medicines and prescribing, often perceived as most valuable to early career practitioners. Discharge prescribing is often undertaken by junior medical officers, making this cohort an important asset to safe and appropriate prescribing.

However, when respondents were surveyed on the quality improvement and education activities undertaken for junior medical officers, only 60% of respondents noted that either written or verbal feedback was provided by a pharmacist to junior doctors with another 9% giving feedback to the junior doctor’s supervisor. Other frequent forms of education were doctor-led education on pain and opioid supply (20%) and pharmacy led education on opioids (9%). Fourteen per cent of respondents collaborated with Drug and Therapeutic Committees on the production of learning materials and activities.

Approximately one quarter of respondents indicated that education was not undertaken by their pharmacy department. Many private hospital respondents’ comments specifically noted that junior medical officers are not employed by private hospitals.

Section 7. Innovation

7.1 Incidence of innovation by hospital pharmacies to address inappropriate opioid use in opioid naive patients

The results provided by respondents revealed **just under 20% of hospitals had been able to trial an intervention** either in the pharmacy department or in partnership with their multi-disciplinary team. Predominantly, interventions described by respondents focused on auditing opioid prescribing and/or supply.




Figure 17. Has your hospital undertaken research or implemented interventions/innovations to address inappropriate opioid use in opioid naive patients in last five years?

Section 8. Variation in responses between metropolitan and regional hospitals

Service provision was significantly less comprehensive in regional and rural hospitals. A greater proportion of metropolitan hospitals had acute pain programs, opioid stewardship programs, ambulatory pain programs, and pre-admission clinics in comparison to regional and rural hospitals. Programs that did exist in regional or rural hospitals were more likely to be 'limited/informal'.

The barriers reported for provision of services in rural/regional hospitals were similar to those cited for metropolitan hospitals, but with some additional issues related to size, such as the need for economies of scale and the challenge of a small workforce. A **lack of medical staff with expertise was a more commonly cited barrier in regional/rural hospitals** than in metropolitan hospitals (35% vs 17%). However, a **lack of organisational support was less of a barrier in regional/rural hospitals** than in metropolitan hospitals, regarding medical department (33% vs 41%), pharmacy department (35% vs 43%) and hospital management (51% vs 66%).




Figure 18. Metropolitan vs Regional/rural: What are the barriers to your hospital site introducing the services that are currently NOT offered?

Pharmacists in regional and rural hospitals were less likely to review the last 48 hours of analgesia use to determine appropriate prescription of analgesia medicines upon **discharge in regional/rural hospitals than metropolitan hospitals** (18% rarely or never, compared to 10%).




Figure 17 Metropolitan vs Regional/rural: Do ward/medical unit pharmacists review the last 48 hours of analgesia use to determine appropriate prescription of analgesia medicines and quantity upon discharge?

Similar levels of provision of discharge summaries and updated medicines lists to patients' community care providers were reported. **However, supply of pain management plans and opioid de-escalation plans were even less common in regional/rural hospitals** (2% and 6% respectively) than in metropolitan hospitals (14% and 10% respectively).




Figure 18. Metropolitan vs Regional/rural: Does the ward/medical unit pharmacist provide any of these documents to the patient's community care providers? (Type of document)

Reporting to most audiences is less frequent and formalised in regional or rural hospitals. For example, **37% of respondents indicated there was no reporting to the Drug and Therapeutics Committee**, 51% indicated there was ad hoc reporting and 12% indicated there was regular reporting annually at least. Corresponding figures reported for metropolitan hospitals were 28% (no reporting), 51% (irregular) and 21% (regular reporting). In all cases this is a small minority of hospitals.




Figure 19. Metropolitan vs Regional/rural: Does the ward/medical unit pharmacist provide any of these documents to the patient’s community care providers? (Frequency) (Regularly defined as at least annually)

Discussion of findings and implications for service provision

It is accepted that whenever and wherever Australians are receiving care through the health system, that the care should be safe and of high quality. This is the fundamental cornerstone of the Australian Charter of Healthcare Rights²⁴.

When delivering services and judging on the quality within the healthcare system all aspects of quality including safety, effectiveness, efficiency, timeliness, equity with a patient-centred focus must be considered. Through the National Medicines Policy there is clear guidance on the delivery of better health outcomes for all Australians, and for this to be achieved medicines should be used judiciously, appropriately, safely and efficaciously.

It is established that there are significant risks and unnecessary harm associated with the use of opioids in Australia. This snapshot of practice within Australian hospitals highlights that Quality Use of Medicines has not yet been achieved, as the judicious, appropriate, safe and efficacious use of opioids is not routinely occurring when we examine the current use of opioids within the Australian healthcare system. Data published in the *Australian Atlas of Healthcare Variation*²⁵ also supports this analysis as significant variation in opioid prescribing is documented nationally, demonstrating that consistent high-quality care is not being provided.

Quality Use of Medicines including opioids is a priority for Australian healthcare. Individually this refers to the process of selecting patient management options wisely, choosing suitable medicines and using medicines safely and effectively. Systemically this involves the use of evidence-based guidelines by a competent workforce, support for the role of Drug and Therapeutics Committees, appropriate audit and research, and adequate access to practitioners for delivery of care. In hospitals delivery of Quality Use of Medicines involves a wide range of partnerships across medical, nursing and pharmacy teams.

This paper comprises the results of an online survey of hospital pharmacists working in public and private Australian hospitals. Patient-centred, progressive and committed to evidence-based practice, SHPA members are hospital pharmacists, technicians and interns who prioritise patient care every day. The survey was completed by 135 Australian hospital facilities and reflects feedback from Directors of Pharmacy and their delegates regarding the provision of pharmacy services, workload, prescribing practice and dispensing activities.

Given the extensive information provided by respondents, this discussion is limited to key findings. A preliminary review of the findings in this paper indicates that variations in access to pharmacy services mean some patients are not provided with adequate medicines reviews, appropriate counselling and tailored supply of high-risk medicines including opioids. In some hospitals, pharmacists may be an under-utilised resource to support prescribing, curb oversupply and educate patients, to reduce the impact of opioid harm. Variation in the provision of specialised pain services may also disadvantage patients accessing smaller hospitals, or those outside metropolitan centres.

1. Service provision

Provision of acute pain services, pain management clinics and opioid stewardship

Opioids are an important therapy in the treatment of pain. In Australia, acute and persistent pain are common conditions with persistent pain experienced by 15% of people in a variety of settings with a wide range of causes²⁶. Pain may be acute and resolve after physical recovery and treatment, or it can be persistent and experienced for more than three months.

For people undergoing surgery, post-surgery pain is common and analgesia medicines are a mainstay of treatment. In Australia, acute pain services and pain management clinics are the most common forms of tailored interventions for pain and are internationally accepted. According to a review of pain management services, undertaken by the New South Wales Government, acute pain services have been introduced throughout major hospitals²⁷. The NSW literature review indicated that internationally, acute pain services were primarily focused on post-surgery pain management and patients with complex pain issues and that the

mainstay is pharmacological and non-pharmacological treatments, such as balanced activity and rest, surgery or other procedures. In contrast to acute pain services, it reported that pain management clinics are committed to a biopsychosocial view of pain, tend to focus on complex and persistent pain, and are staffed by multidisciplinary teams. While published articles support the provision of these services, little consistent information is available about details of service provision.

SHPA has utilised grey literature where appropriate in our findings regarding adoption of comprehensive models²⁸ specifically addressing pain management in an acute setting, as information was surprisingly limited and implementation inconsistent. Results show that access to pain services for Australians remains variable, especially for those living in regional and rural areas, which reflects concerns raised in the *Australian Atlas of Healthcare Variation* charting variation in opioid prescribing²⁵. Sixty-one per cent of respondents' facilities provide an inpatient acute pain service, while 27% have an ambulatory or outpatient pain management clinic for post-surgical patients. This leaves a substantial proportion of patients without access to evidence-based pain services, especially when attending private hospitals, or in regional and rural locations. It is also unclear from respondents how these services compare and what differences exist, with significant reporting of 'informal', piecemeal or temporary services. SHPA's recent work developing a *Standard of Practice for Pain Management in Pharmacy Services* has brought together examples of effective service models to encourage greater consistency.

A component of analgesia stewardship, opioid-focused stewardship addresses the prevention of inappropriate opioid prescribing and supply, among other quality and safety activities. As an emerging model, it is not surprising that the prevalence of opioid stewardship services is low (4.5% of respondents had a formal opioid stewardship program). Not-yet-published evidence from a Victorian tertiary hospital regarding opioid stewardship indicates great potential for reducing harms when supported by adequate funding and management. The recent Victorian Inquiry into Drug Law Reform has recommended that a sector-wide trial based on an opioid stewardship model be implemented to promote and audit best practice regarding the prescribing and use of medications with potential for misuse²⁹. This pharmacist-led model is also supported by SHPA's *Standard of Practice for Pain Management in Pharmacy Services*. However, barriers identified for establishing or expanding any of the outlined pain services (acute pain services, pain management clinics or opioid stewardship) appear substantial, dominated by a lack of funding and hospital management support. This provides an ongoing challenge for Directors of Pharmacy seeking to innovate and expand services to provide safe and high-quality care to patients.

Of the reported acute pain services and pain management clinics, more than 90% did not fully utilise pharmacists' clinical skills expertise, even though the value and impact of clinical pharmacy skills are core to the effective use of medicines, and many successful models exist which incorporate pharmacist roles³⁰. Acute pain management guidelines published by the Australian and New Zealand College of Anaesthetists (ANZCA) stipulate that acute pain services should involve close liaison with pharmacists³¹, however, more than a third of respondents (34%) indicated their health service's acute pain service did not have pharmacist involvement. While innovative pharmacy services have developed a range of pharmacy positions aligned with medical units to address emerging health crises (e.g. antimicrobial resistance, mental health, opioid harm), at present these roles appear to be predominantly limited to a sparse number of principal referral hospitals which may be attributed to the current scarcity of innovation resources available in many hospitals. Of the health services with an acute pain service, 72% believed their services should be expanded.

2. Patient journey

Medication reconciliation

The delivery of pharmacy services to patients during their time in a hospital is defined by a range of government³² and sector clinical governance standards outlining the provision of medication reconciliation, medication review, medication management, discharge liaison and antimicrobial stewardship. These clinical activities, which collectively support medication safety, are captured under the term 'Quality Use of Medicines' (QUM). A crucial component of QUM is medication reconciliation at the time of admission to hospital, which includes verification and documentation of all patient's current medications, to ensure an effective transition of

care and reduces disruption to their established medicine regimen. Before pharmacist-led medication reconciliation became routine in Australian hospitals, rates of error were reported to be as high as one omitted medicine in every two admissions³³ with this error rate remaining applicable in some hospitals. Undertaking medication reconciliation during a patient's stay is a national healthcare standards requirement with reconciliation by pharmacists prior to surgery accepted practice internationally³⁴.

The value of pharmacists in reducing errors in medication reconciliation is well supported by evidence³⁵. In a surgical setting, medication reconciliation is vital to establish potential opioid tolerance, detect potential complications and interactions with other medications and influences requirements for post-surgery pain management. The findings highlight that gaps exist in the provision of medication reconciliation upon admission for all patients, with 37% of respondents indicating that medication reconciliation was provided for some but not all patients, 9% by non-pharmacists and 4% not at all. These findings present a safety and quality risk for patients where additional review is not provided, or first review is delayed during their hospital stay. Limited access to information from prescription monitoring services was also reported, despite the important role this plays in enabling medication reconciliation.

Review of patients

A key aspect of appropriate care is the review of patients during their hospital stay by pharmacists. The responsibilities of the pharmacist managing hospitalised patients on a surgical ward typically include review of patients who did not receive medication reconciliation at admission, as well as the provision of advice to patients about appropriate pain management including analgesia use. Almost all respondents indicated that pharmacists provide a similar service at their facility, however half of the respondents indicated it was provided only to patients identified as 'high-risk'. This indicates that pharmacy review is not provided routinely to all patients, and there is significant variability between hospitals as to who does, and who does not receive a review.

SHPA's *Standard of Practice for Clinical Pharmacy Services* identifies 13 factors to be considered by pharmacists deciding which patients to prioritise for clinical pharmacy care as well as another eight medicine factors¹⁴, yet there is a lack of evidence showing this is implemented consistently. The major factors considered by most respondents in prioritising clinical pharmacy services are multiple chronic conditions/comorbidities (65%), age (59%), current anticoagulant use (59%) and renal or hepatic impairment (47%). Significant gaps such as risk factors relating to opioid tolerance or naivety were evident.

According to SHPA standards, all patients admitted to a surgical ward should be prioritised for clinical pharmacy services as it reflects their patient factors and risk of re-hospitalisation. The stratifying of patient risk to determine patient care is common in healthcare and relatively sound, however, results indicate that gaps in pharmacy services exist which exclude patients from appropriate care. The sheer level of demand and complexity of patient needs in an acute setting may contribute to patients with uncomplicated surgical outcomes receiving lower priority, yet a surgical procedure's simplicity is not proven to correlate with a lower risk of opioid harm⁴.

During hospital stays all patients are visited by the treating doctor. In public hospitals this commonly occurs as part of a multi-disciplinary team ward round which provides an opportunity for members of the multi-disciplinary team (consultants, junior doctors, and allied health professionals including pharmacists) to jointly engage with patients and discuss progress and treatment. Ward rounds are regarded as a key aspect of best-practice to provide patient-centred care. In the last two decades, pharmacists have been progressively included as key members of multi-disciplinary teams in hospitals, however consistent involvement in ward rounds remains a challenge for many respondents. Only 9% were able to do so routinely, with 31% doing so 'if they had time' and the overwhelming majority of pharmacists (57%) not attending. Typically, private hospitals which are visited by consultant specialists rather than staff specialists, do not facilitate multi-disciplinary ward rounds.

3. Use of medicines to treat acute pain in opioid naive patients

In Australia and internationally opioids are classified as 'high-risk' medicines due to their extensive adverse effect profile, in particular, their sedative and respiratory depressant effects. More broadly, long-term use of opioids can impair cognitive function and precipitate dependency and addiction. Efforts to reduce harm have initially focussed on opioid prescribing in the community. In recent years it has become widely accepted that hospital prescribing, and hospital initiation of opioids plays an important role⁴. New Zealand research indicates that while the majority of prescribing occurs in the community, 70% is initiated in hospitals with 17% of patients continuing opioid use long-term³⁶. The dose and quantities of opioid medicines prescribed at discharge have been identified as a risk factor for long-term use³⁷ with each refill or an additional week being associated with a 44% increase in the rate of misuse³⁸. Hence, it is increasingly accepted that the risk of opioid harm results from a combination of dose, quantity, surgical procedure and patient risk factors³⁹.

Commonly prescribed analgesia for acute pain

According to respondents, a typical treatment for acute pain in opioid naive patients at Australian public and private hospitals is likely to include a combination of immediate-release opioids, sustained-release opioids and non-opioid analgesia. During recovery from surgery patients are generally prescribed maximal doses of paracetamol to provide baseline analgesia, with adjunct opioid analgesia to treat severe pain as necessary – immediate-release oral opioids is a cornerstone of acute pain management. This may be complemented by other non-opioid analgesia such as non-steroidal anti-inflammatory drugs and partial/mixed opioids (e.g. tramadol, tapentadol) if appropriate. As per the recent statement from ANZCA, and Analgesic Therapeutic Guidelines, sustained-release opioids are not recommended for use in the management of patients with acute pain⁴⁰ however they are currently reported to be used by 77% of respondents in the treatment of acute pain which may indicate future difficulty in changing clinical habits.

Commonly prescribed analgesia at discharge

It would be reasonable to expect differences in prescription trends during discharge as opposed to admission, with recovery from surgery tending to lessen the need for analgesia – especially opioid-based analgesia – upon discharge. However, trends of supply during discharge were very similar to admission: immediate-release opioids (97% at discharge vs 97% during admission), non-opioid analgesia (97% vs 96%), sustained-release opioids (oral formulation) (71% vs 77%) and partial/mixed opioids (66% vs 74%). Again, the high rate of sustained-release opioids provided both during admission and upon discharge for the treatment of acute pain is concerning. ANZCA's statement specifically mentions risk for first-time users, the elderly and people on other medications⁴⁰. Whilst prescription of transdermal sustained-release opioid patches was lower overall than other analgesia medicines, 22% of respondents recorded their provision during admission, as well as 11% at discharge. This is also concerning as transdermal sustained-release opioid patches are indicated for persistent, but not acute, pain management. The Royal Australian College of General Practitioners has recently supported the introduction of standardised discharge management for people taking opioids to address some of these prescribing practices⁴¹.

Regional variation in prescribing of opioids

It is worth noting use of sustained-release opioids for treatment of acute pain in inpatients in Victoria, New South Wales, Western Australian and Queensland was nearly three-fold that of South Australia, with more than 70% of respondents reporting sustained-release opioids as standard treatment compared to 20%. Tasmania was the next lowest with 67% reported. At discharge a similar trend was present with South Australia reporting 10% use compared to 70% nationally, with Tasmania again the next lowest with 33%. In contrast, use of immediate-release opioids for inpatients and at discharge was consistent nationally. More analysis is required to assess the cause of these results, but anecdotal feedback indicates that South Australia's adoption of a state-wide formulary process may contribute. Defined after broad consultation the current South Australian Medicines Formulary does not list sustained-release opioids for acute pain (only for chronic pain not responsive to non-opioid analgesia) meaning they will not be supplied by the hospital pharmacy. The formulary also informs the development of all SA Health guidelines⁴². Given the risk of harm is considerably higher with sustained-release opioids compared to immediate-release opioids (24.5% versus

3.5%) this formulary driven practice is of great interest⁴³ and demonstrates the value of strong, collaborative governance processes.

Access to pharmacy counselling and review for patients taking opioids

As medicines experts working in an acute setting, hospital pharmacists have a key role as a safeguard to reduce the risk of inappropriate medicines prescription, supply and use. Pharmacists also have a regulatory obligation to ensure medicines are safe for patients. A recent coroner's report described pharmacists as having a 'a vital failsafe role in preventing inappropriate prescribed medication from reaching patients'⁴⁴. In addition to counselling patients on individual medicines, pharmacists are expected to review medicines prescribed for patients being discharged from hospital, in order to assess appropriateness of the dosage, frequency, side effects and efficacy and if any prescription contains inappropriate medicine therapy. For patients receiving opioids this intervention is essential given the research showing a link between prescriptions of more than five days and an increased risk of continued opioid use³⁷. According to our results, substantial gaps exist in the likelihood of pharmacists ensuring patients had their medicines reviewed before discharge with less than a quarter of respondents (23%) 'extremely likely' to review a patient's medicines prior to discharge to inform appropriate prescribing. The importance of hospital pharmacists reviewing medicines initiated during admission and their suitability for supply upon discharge, has been previously recognised, but little seems to have changed⁴⁵, with only 53% of respondents stating that they always or often review the patient's last 48 hours of analgesia use to determine appropriate supply upon discharge.

Only 39% of respondents indicated that patients would 'always' receive counselling on opioids post-surgery upon discharge, and another 40% indicated it was 'often'. This finding implies the majority of patients are at risk of missing out on counselling for high-risk medicines at discharge. Patients undergoing day surgery were at most risk of missing out on counselling with only 14% of respondents always providing counselling for this cohort. Throughout the comments, many respondents from private and public facilities indicated their day surgery units were often not supported by a hospital pharmacist. This is concerning as SHPA recommendations for clinical pharmacy services for same-day admissions is 1 FTE for every 22 beds¹⁴.

Supply of opioids at discharge

Hospital pharmacists facilitate the supply of opioids from the dispensary as prescribed when the patient is being discharged from hospital. Policies establishing how many days of medicine a patient should receive on discharge differ significantly depending on factors including whether the state/territory is a signatory to the Pharmaceutical Benefit Scheme (PBS) in hospitals, whether the hospital is public or private and whether medicines are dispensed by the in-house hospital pharmacy or outsourced. Across Australia recommended amounts for medicines provided at discharge vary from three to thirty days' supply.

As discussed previously review of a patient's use of analgesia is best practice to inform discharge prescribing. In addition, other research has indicated that 19% of patients prescribed oxycodone on discharge from a large Australian teaching hospital had not needed any opioid in the 24 hours prior, raising questions whether supply was necessary⁴⁶. In SHPA results more than 70% of respondents reported that even when opioids had not been required in the prior 48 hours, they were still provided to take home 'just in case'. This is concerning given research finding the provision of a prescription or supply of opioids places the patient at higher-risk of opioid harms, which may be unnecessary in these cases. More information into the prevalence of this practice would be beneficial. Feedback from medical colleagues indicates that prescribing at discharge is often delegated to junior doctors who may find it difficult to withstand pressure from patients⁴⁷. Apart from increasing individual risk this can result in unnecessary opioids in patients' homes and community which are inappropriately shared with family and friends or diverted for illicit, recreational purposes⁴⁸.

In an effort to improve patient flow and bed availability, some respondents indicated that their facility made efforts to increase the efficiency of discharge by writing up discharge prescriptions before discharge is confirmed (61%) and before surgery (21%), as well as dispensing medicines before discharge is confirmed (39%) and before surgery (10%), often in pre-packed quantities. This is a stark contrast to other facilities which routinely break up medicine packs into smaller quantities, often less than PBS pack sizes, to reduce risk and provide greater opportunity for personalised prescribing. While the risks presented by these efficient

practices may be mitigated in some settings by proactive review and revision, they do represent a departure from patient-centred practice and contravene professional guidelines. Clearly significant variance exists in practice with hospitals implementing a wide range of activities to pursue goals of patient care.

4. Hospital pharmacy and the transition of care

Information provided at discharge

The transition of care from hospital to the community, remains a key vulnerability for medicine management with more than 50% of medication errors occurring at transitions of care⁴⁹. Central to complaints from community care providers is the inadequate supply of information from hospitals to aid reconciliation with any hospital-initiated medication changes. There are three key components of information that are required at discharge: an accurate medication list, a discharge summary detailing changes, and a management plan post discharge.

Our findings reported a strong commitment to providing an updated medicines list (74%) This is a positive step, however not all lists provide the level of detail required for addressing changes in medication. Forty-three percent of respondents reported that they provide a discharge summary. However additional comments indicated this was often only for 'high-risk' patients which indicates that many patients leaving hospitals (including surgical patients) would not receive a discharge summary. This variance is well-recognised as a key gap in care that necessitates resolution. The limited capacity of pharmacists to provide discharge summaries for all patients with detailed descriptions of any medication changes has implications for safety given the higher quality of pharmacist discharge summaries and the significant rate of errors of high and extreme risk found in medication summaries for general medical patients³⁵.

Equally concerning is the absence of management plans, such as pain management plans and opioid de-escalation plans, for more than 90% of patients, which would be of assistance to General Practitioners and Community Pharmacists. Again, limited hospital pharmacy capacity to produce pain management plans potentially disadvantages patients who have undergone routine surgery, delaying de-escalation of therapy and contributing to risk of opioid harm. It should be noted that transition of care pharmacy services associated with hospitals, which provide additional support for the development of management plans, are available in some areas. These programs vary greatly in their structure, governance and provision of services, and it is likely that survey respondents were not responding on behalf of specific transitional services that may be accessible for their patients on discharge.

5. Reporting on opioid use

Opioid reporting

The reported increase in opioid prescribing has prompted increased interest in possible interventions and regulation including recent correspondence to outlier community prescribers from Australia's Chief Medical Officer. However, the role of hospitals as the site of initial opioid prescription appears unrecognised by most. Some hospitals are undertaking audits of opioid prescribing, and looking at provision of review or counselling, yet with only a minority of respondents providing regular report information, the results are challenging for pharmacy leaders driving innovation.

Fifty-one per cent of respondents provided information to the Drug and Therapeutics Committee and pharmacy departmental staff when requested and only 47% to hospital management. With respect to reporting for the medical department, nursing department and local hospital networks, the majority of respondents reported they 'never' provided information about opioid prescribing (51%, 60% and 63% respectively). This finding indicates that pharmacy data and reporting capacity is underutilised by many hospitals which may limit their capacity to undertake innovative interventions to support judicious prescribing. An example of an intervention requiring pharmacy reporting is academic detailing, more commonly undertaken in General Practice. Australian and international studies of academic detailing have shown great promise in reducing opioid prescribing in hospitals⁵⁰.

6. Education

Pharmacists with expertise in opioids and the management of pain are highly valued as a resource. Pharmacists perform this educative role both formally and informally, through ward rounds or in team meetings, in opportunities to collaborate with specialised teams such as acute pain teams, and through the provision of information including reports as discussed above.

Most commonly pharmacists were able to provide information relating to medication error or adverse events relating to opioids (53%), and these were discussed by the medication safety team (41%) providing broad feedback and education for hospital dissemination. Whilst few hospitals utilised comprehensive reports, of those who did provide information approximately a quarter of respondents reported it was used to directly inform the education of pharmacists, doctors and nurses. Sixty-nine percent of respondents provided either verbal or written feedback to junior doctors or their supervisors. Junior doctors were identified as a particular focus due to their frequent responsibility for prescribing at discharge of patients, and their limited opportunity to gain previous experience in prescribing.

Prescriber education is a valued component of the Quality Use of Medicines, and 25% of respondents provided pharmacist-led education of opioid prescribing and supply which is a promising result given the capacity issues evident in opioid and pain services. However, a significant proportion of respondents (25%) reported that their pharmacy department did not undertake education, and these included both public and private hospital facilities. This lack of a 'check and balance' on prescribing practice is concerning.

7. Innovation in practice

In the current healthcare climate hospital pharmacies are under significant pressure to provide enhanced clinical services, dispense an increased volume of medicines, provide more complex treatments and absorb additional administration. Despite this, there continues to be strong interest in research and innovation to address emerging health issues related to medicines such as reducing opioid-related harm.

This study identified a number of these initiatives including new program models, prescribing toolkits and state-wide governance models that were outlined by respondents from major metropolitan hospitals in Melbourne, Adelaide, Sydney and Brisbane. Notably South Australia's state-wide formulary model and prescribing support which enabled a significant reduction in the use of the sustained-release opioids both during admission and at discharge, while Alfred Health's adaption of the antimicrobial stewardship model to opioid stewardship shows value for harm reduction. Private hospital St Vincent's in Sydney has led prescriber education by investing in hospital pharmacy reporting software (PharmaLytix) which strongly influenced improved prescribing practices.

Nevertheless, these examples primarily reflect the experiences of larger hospitals and remain the exception rather than the rule. Unfortunately, only 20% of respondents were able to list an opioid harm reduction innovation or intervention attempted by their facility. The small pool of capacity for innovation potentially limits benefits to vulnerable patients and health services. Additional comments repeatedly focused on the requirement for auditing, and studies and trials, before any intervention could be established. The requirement for each hospital to have the need proven on a local level, and the establishment of a business case for any trial of service change is an impediment to systemic change and innovation. While the need for any service change to be initially proven and tested is reasonable, in practice it can result in a waste of precious health funding resources as each facility repeats the same process to reach the same outcome. SHPA believes that implementation of innovation at a systemic level, such as federal government support for opioid stewardship similar to their support of antimicrobial stewardship, would offer a more effective approach. Further collaborations and profession-wide consensus of evidence-based practice improvements to reduce potential harm need to be progressed and implemented into practice.

8. Next steps

This work aims to provide an insight into current practices and to identify areas for improvement and innovation to reduce opioid-related harms.

SHPA's inaugural Medicines Leadership Forum in July 2018 will provide an opportunity for reflection and discussion of the key findings with a range of medical and health stakeholders and result in the development of recommendations. These will be published by SHPA as part of a report on this issue to support further discussions with stakeholders including hospitals regarding service provision, clinical care and governance.

Conclusion

There is a need to ensure appropriate use of opioids when needed whilst minimising potential for harm. There are concerns that people experiencing less serious acute pain are at increasing risk of opioid harm, and there is an urgent need to examine current practice in hospitals.

SHPA's key findings indicate that variations in practice in hospitals impact on the care provided to surgical patients at risk of opioid-related harm and these include:

- The provision of specialised services for patients with pain is varied, with a considerable range reported in relation to the provision of acute pain services and pain management clinics for post-surgical patients, especially in regional and rural areas.
- Sizeable gaps existed in the provision of medication reconciliation, clinical review, analgesia and pain management advice and review of analgesia use before discharge, for patients attending both public and private hospitals.
- Pharmacists report extremely high use of sustained-release opioids in treatment of acute pain for opioid naive surgical patients.
- Current practices relating to the prescribing and dispensing of opioids at discharge result in excess quantities given to patients with the potential to lead to preventable harm.
- Information provided at hospital discharge (medication lists, discharge summaries and medication plans) is inconsistent and many patients and their General Practitioners are not receiving the appropriate information.
- Clinical pharmacy capacity at hospitals with substantial surgical patient loads may not meet patient need.
- Risk factors for opioid harm are not commonly prioritised by contemporary clinical pharmacy services.
- Clinical pharmacy prioritization tools used in a hospital setting require review to ensure they address the risk of long-term misuse and associated harms.
- A range of innovative strategies which enable improved patient care alongside prescriber and governance support (including opioid stewardship) should be considered for expansion. Results also provided evidence of the value of hospital pharmacies equipped to innovative and empowered to address public health challenges.
- Statewide interventions which capitalize on pharmacy expertise through effective governance and engagement across pharmacy, medical and nursing workforces delivered positive outcomes in areas of prescribing, supply and prescriber education.

This work was intended to provide an insight into current practices and to identify areas for improvement and innovation for reducing opioid harms. SHPA's inaugural Medicines Leadership Forum in July 2018 will provide an opportunity for reflection and discussion of the key findings with a range of medical and health stakeholders and result in the development of recommendations. These will be published by SHPA as part of a report on this issue to support further discussions with stakeholders including hospitals regarding service provision, clinical care and governance.

References

- ¹ Australian Bureau of Statistics. Causes of Death, Australia, 2016. Australian Bureau of Statistics. 2018. Available from: <http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/3303.0~2016~Main%20Features~Drug%20Induced%20Deaths%20in%20Australia~6>
- ² Compton WM, Boyle M, Wargo E. Prescription opioid abuse: Problems and responses. *Prev Med*. 2015;80:5-9. Available from: <https://www.sciencedirect.com/science/article/pii/S0091743515001036>
- ³ Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. *Drug Alcohol Depend*. 2006;81(2):103-7. Available from: [https://linkinghub.elsevier.com/retrieve/pii/S0376-8716\(05\)00182-1](https://linkinghub.elsevier.com/retrieve/pii/S0376-8716(05)00182-1)
- ⁴ Burcher KM, Suprun A, Smith A. Factors for Opioid Use Disorders in Adult Postsurgical Patients. *Cureus* 2018;.10(5): e2611. Available from: <https://www.cureus.com/articles/10503-risk-factors-for-opioid-use-disorders-in-adult-postsurgical-patients>
- ⁵ Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. *Clin J Pain* 2014;30:557–64. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032801/>
- ⁶ Australian Institute of Health and Welfare. Admitted patient care 2016–17: Australian hospital statistics. Health services series no. 84. Cat. no. HSE 201. Canberra. 2018: AIHW. Available from: <https://www.aihw.gov.au/getmedia/acee86da-d98e-4286-85a4-52840836706f/aihw-hse-201.pdf.aspx?inline=true>
- ⁷ Meissner W, Coluzzi F, Fletcher D, Huygen F, Morlion B, Neugebauer E, et al. Improving the management of post-operative acute pain: priorities for change. *Curr Med Res Opin*. 2015;31(11):2131-43. Available from: <https://www.tandfonline.com/doi/full/10.1185/03007995.2015.1092122>
- ⁸ Schechter L. Advances in postoperative pain management: the pharmacy perspective. *Am J Health Syst Pharm*. 2004;61(suppl 1): S15-S21. Available from: http://www.ajhp.org/content/61/suppl_1/S15
- ⁹ Alfred Health. Stewardship Programs. 2018. Available from: <http://www.alfredpharmacy.org.au/our-department/cmus/stewardship/>
- ¹⁰ American Society of Health-System Pharmacists. Opioid Stewardship: What, Why, & How. 2017. [Publication]
- ¹¹ Genord C, Frost T, Eid D. Opioid exit plan: A pharmacist's role in managing acute postoperative pain. *J Am Pharm Assoc* (2003). 2017;57(2, Supplement):S92-S8. Available from: [https://linkinghub.elsevier.com/retrieve/pii/S1544-3191\(17\)30016-X](https://linkinghub.elsevier.com/retrieve/pii/S1544-3191(17)30016-X)
- ¹² Pharmaceutical Society of Australia Ltd. National competency standards framework for pharmacists in Australia. Deakin: Pharmaceutical Society of Australia. 2016. Available from: <https://www.psa.org.au/download/standards/competency-standards-complete.pdf>
- ¹³ Princess Alexandra Hospital. My Pain Pharmacist role position description. 2018. [In correspondence with Kristin Hore].
- ¹⁴ The Society of Hospital Pharmacists of Australia. Standard of Practice in Clinical Pharmacy Services. *Journal of Pharmacy Practice and Research*. 2013;43 (2). Available from: <https://www.shpa.org.au/resources/standards-of-practice-for-clinical-pharmacy-services>
- ¹⁵ Spinewine A, Dhillon S, Mallet L, Tulkens PM, Wilmotte L, Swine C. Implementation of Ward-Based Clinical Pharmacy Services in Belgium—Description of the Impact on a Geriatric Unit. *Ann Pharmacother*. 2006;40(4):720-8. Available from: http://journals.sagepub.com/doi/abs/10.1345/aph.1G515?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed#articleCitationDownloadContainer
- ¹⁶ Kaushal R, Bates DW, Abramson EL, Soukup JR, Goldmann DA. Unit-based clinical pharmacists' prevention of serious medication errors in pediatric inpatients. *Am J Health Syst Pharm*. 2008;65(13):1254-60. Available from: <http://www.ajhp.org/cgi/pmidlookup?view=long&pmid=18574016>
- ¹⁷ Government of South Australia SA Health. Clinical Practice Guideline for the pain management and opioid safety. (2015). Available from: <https://www.sahealth.sa.gov.au/wps/wcm/connect/4ef07c8047fe4149976bd721d1663cdf/Pain+Management+and+Opioid>

- [d+Safety_Mar2015.pdf?MOD=AJPERES&CACHEID=ROOTWORKSPACE-4ef07c8047fe4149976bd721d1663cdf-m9T6uoY](#)
- 18 Schug SA, Palmer GM, Scott DA, Halliwell R, Trinca J; APM:SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Acute Pain Management: Scientific Evidence (4th edition), ANZCA & FPM, Melbourne. 2015. Available from: http://fpm.anzca.edu.au/documents/apmse4_2015_final
 - 19 Rennke S, Ranji SR. Transitional Care Strategies From Hospital to Home: A Review for the Neurohospitalist. The Neurohospitalist. 2015;5(1):35-42. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4272352/>
 - 20 Lumish R, Goga JK, Brandt NJ. Optimizing Pain Management Through Opioid Deprescribing. J Gerontol Nurs 2018 01;44(1):9-14. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/29355883>
 - 21 The Australian Commission on Safety and Quality in Health Care. National guidelines for on-screen presentation of discharge summaries. ACSQHC: Sydney.2017. Available from: <https://www.safetyandquality.gov.au/wp-content/uploads/2018/02/National-guidelines-for-on-screen-presentation-of-discharge-summaries-Feb-2018.pdf>
 - 22 NSW Health. Chronic Pain Management. 2018. Available from: <http://www.health.nsw.gov.au/pharmaceutical/doctors/Pages/chronic-pain-medical-practitioners.aspx>
 - 23 Duguid M. & Cruickshank M. (eds) Antimicrobial stewardship in Australian hospitals. Australian Commission on Safety and Quality in Health Care. Sydney. 2010. Available from: <https://www.safetyandquality.gov.au/wp-content/uploads/2011/01/Antimicrobial-stewardship-in-Australian-Hospitals-2011.pdf>
 - 24 Australian Commission of Safety and Quality in Healthcare. Australian Charter of Healthcare Rights. 2008. Available from: <https://www.safetyandquality.gov.au/national-priorities/charter-of-healthcare-rights/>
 - 25 Australian Commission of Safety and Quality in Healthcare. Australian Atlas of Healthcare Variation. 2015. Available from https://www.safetyandquality.gov.au/wp-content/uploads/2015/11/SAQ201_01_FrontSection_v10_FILM_TAGGED-3-Key-findings-and-recommendations.pdf
 - 26 Miller A, Sanderson K, Bruno R, Breslin M, Neil AL. The prevalence of pain and analgesia use in the Australian population: Findings from the 2011 to 2012 Australian National Health Survey. Pharmacoepidemiol Drug Saf. 2017;26(11):1403-10. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/pds.4301>
 - 27 Conway J, Higgins I. Literature review: models of care for pain management: final report. State Government of New South Wales, editor. 2011. Available from: <http://www.health.nsw.gov.au/PainManagement/Documents/appendix-3-literature-review.pdf>
 - 28 Werner MU, S holm L, Rotb ll-Nielsen P, Kehlet H. Does an Acute Pain Service Improve Postoperative Outcome? Anesth Analg. 2002;95(5):1361-72. Available from: https://journals.lww.com/anesthesia-analgesia/fulltext/2002/11000/Does_an_Acute_Pain_Service_Improve_Postoperative.49.aspx
 - 29 Parliament of Victoria. Inquiry into drug law reform. In: Law Reform, Road and Community Safety Committee, editor. Victoria. 2018. Available from: https://www.parliament.vic.gov.au/images/stories/committees/lrrcsc/Drugs_/Report/LRRCSC_58-03_Full_Report_Text.pdf
 - 30 Australian Commission on Safety and Quality in Health Care. National Safety and Quality Health Service Standards guide for multi-purpose services and small hospitals. ACSQHC: Sydney, 2017. Available from: <https://www.safetyandquality.gov.au/wp-content/uploads/2017/12/National-Safety-and-Quality-Health-ServiceStandards-Guide-for-Multi-Purpose-Services-and-Small-Hospitals.pdf>
 - 31 Australian and New Zealand College of Anaesthetists, Faculty of Pain Medicine. Guidelines on Acute Pain Management. 2013. Available from: <http://www.anzca.edu.au/documents/ps41-2013-guidelines-on-acute-pain-management.pdf>
 - 32 Australian Commission on Safety and Quality in Health Care. National Safety and Quality Health Service Standards. ACSQHC, editor. Sydney. 2012. Available from: <https://www.safetyandquality.gov.au/wp-content/uploads/2011/09/NSQHS-Standards-Sept-2012.pdf>

- ³³ Roughead L, Semple S, Rosenfeld E. Literature Review: Medication Safety in Australia. In: Australian Commission on Safety and Quality in Health Care, editor. Sydney. 2013. Available from: <https://safetyandquality.gov.au/wp-content/uploads/2014/02/Literature-Review-Medication-Safety-in-Australia-2013.pdf>
- ³⁴ Arenas-Villafranca JJ, Moreno-Santamaría M, López Gómez C, Muñoz Gómez-Millán I, Álvaro Sanz E, Tortajada-Goitia B. An admission medication reconciliation programme carried out by pharmacists: impact on surgeons' prescriptions. *European Journal of Hospital Pharmacy*. 2018. Available from: <https://ejhp.bmj.com/content/early/2018/01/11/ejhpharm-2017-001392.full>
- ³⁵ Tong EY, Roman CP, Mitra B, Yip GS, Gibbs H, Newnham HH, et al. Reducing medication errors in hospital discharge summaries: a randomised controlled trial. *Med J Aust*. 2017;206(1):36-9. Available from: https://www.mja.com.au/system/files/issues/206_01/10.5694mja16.00628.pdf
- ³⁶ Ministry of Health. (2014). Pharmaceutical collection. Cited in BPAC. Oxycodone: How did we get here and how do we fix it? . *Best Practice Journal*. 2015(62):21-7. Available from: <https://bpac.org.nz/BPJ/2014/July/docs/BPJ62-oxycodone.pdf>
- ³⁷ Shah A, Hayes CJ, Martin BC. Factors Influencing Long-Term Opioid Use Among Opioid Naive Patients: An Examination of Initial Prescription Characteristics and Pain Etiologies. *J Pain*. 2017;18(11):1374-83. Available from: [https://www.jpain.org/article/S1526-5900\(17\)30635-1/abstract](https://www.jpain.org/article/S1526-5900(17)30635-1/abstract)
- ³⁸ Brat GA, Agniel D, Beam A, Yorkgitis B, Bicket M, Homer M, et al. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. *BMJ*. 2018;360. Available from: <https://www.bmj.com/content/360/bmj.j5790>
- ³⁹ Cicero TJ, Ellis MS. The prescription opioid epidemic: a review of qualitative studies on the progression from initial use to abuse. *Dialogues Clin Neurosci*. 2017;19(3):259-69. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741109/>
- ⁴⁰ Australian and New Zealand College of Anaesthetists, Faculty of Pain Medicine. Position statement on the use of slow-release opioid preparations in the treatment of acute pain. 2018. Available from: <http://www.anzca.edu.au/resources/endorsed-guidelines/position-statement-on-the-use-of-slow-release-opioids>
- ⁴¹ The Royal Australian College of General Practitioners. Australian GPs call for reform in pain management to protect patients and reduce risky opioid use. 2017. Available from: <https://www.racgp.org.au/yourracgp/news/media-releases/australian-gps-call-for-reform-in-pain-management-to-protect-patients-and-reduce-risky-opioid-use/>
- ⁴² South Australian Medicines Formulary. Available from: https://extapps.health.sa.gov.au/SAH_DrugFormulary/Account/DrugSearch.aspx
- ⁴³ Deyo RA, Hallvik SE, Hildebran C, Marino M, Dexter E, Irvine JM et al. Association Between Initial Opioid Prescribing Patterns and Subsequent Long-Term Use Among Opioid-Naive Patients: A Statewide Retrospective Cohort Study. *Journal of General Internal Medicine*. 2016 2;1-7. Available from: <https://doi.org/10.1007/s11606-016-3810-3>
- ⁴⁴ Carlin, R. Finding into death with Inquest (Ian Gilbert) coronial report. 2018. Available from: http://www.coronerscourt.vic.gov.au/resources/54c248f3-f7c7-40ea-8134-fa81312025ab/ianjohngilbert_074215.pdf
- ⁴⁵ Nicholas R, Lee N, Roche A. Pharmaceutical Drug Misuse in Australia: Complex Problems, Balanced Responses. In: NCETA, editor. Adelaide. 2011. Available from: http://nceta.flinders.edu.au/files/6113/2823/3742/EN448_Nicholas_2011.pdf
- ⁴⁶ Platis A, Wenzel T. Hospital oxycodone utilisation research study (HOURS). Adelaide: Pharmacy Department Royal Adelaide Hospital: 2011. [Cited in: The Royal Australian College of General Practitioners. A quick briefing document: Discharge Opioid Management. 2018]
- ⁴⁷ HACK. Junior doctors are overprescribing powerful painkillers. *ABC Triple J*. 15 August 2017. Available from: <http://www.abc.net.au/triplej/programs/hack/young-doctors/8805094>
- ⁴⁸ Belcher J, Nielsen S, Campbell G, Raimondo B, Hoban B, Larance B, et al. Diversion of prescribed opioids by people living with chronic pain: Results from an Australian community sample. *Drug and Alcohol Review*. 2014;33(1):27-32. Available from: <https://doi.org/10.1111/dar.12084>
- ⁴⁹ Commonwealth of Australia. National Medicines Policy. Canberra: 2000. [Publication]
- ⁵⁰ Hill MV, Stucke RS, McMahon ML, Beeman JL, Barth RJJ. An Educational Intervention Decreases Opioid Prescribing After General Surgical Operations. *Ann Surg*. 2018;267(3):468-72. Available from: https://journals.lww.com/annalsurgery/Abstract/2018/03000/An_Educational_Intervention_Decreases_Opioid.14.aspx